Vi Chiu
Hematology & Oncology · Los Angeles, CANPI 1992725865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Reporting peaked in 2023 at $537 and has fallen 94.2% since, to $31 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 11 payments — averaging $88.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$280
- Exelixis Inc.$174
- Intera Oncology, Inc$168
- Novartis$161
- Ipsen Biopharmaceuticals, Inc$149
- EMD Serono, Inc.$29
- plus $13 from 1 others
Across 26 payments — averaging $22,047 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$341K
- Astrazeneca UK Limited$108K
- Novartis$78K
- Biontech SE$38K
- United Therapeutics Corporation$8K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Food & beverage$975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $280 |
| Exelixis Inc. | 1 | $174 |
| Intera Oncology, Inc | 1 | $168 |
| Novartis | 1 | $161 |
| Ipsen Biopharmaceuticals, Inc | 1 | $149 |
| EMD Serono, Inc. | 1 | $29 |
| Array Biopharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$174
- Intera 3000 Implantable Pump$168
- ONIVYDE$149
- IMFINZI$135
How this compares
$975 in reported general payments places this provider in the 30th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StivargaRegorafenib | 20 | $454,241 |
| Oxycodone Hcl | 21 | $417 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $379 |
| Ondansetron OdtOndansetron | 14 | $295 |
| Ondansetron Hcl | 14 | $116 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.